Lek Supervisory Board appoints Robert Ljoljo as new President of the Management Board

27. 8. 2019

Lek Supervisory Board appointed Robert Ljoljo, MSc, MBA, as President of the Management Board of Lek effective September 1, 2019. Mandates of current members of the Management Board have been prolonged until the upcoming Supervisory Board meeting in September. 

Robert Ljoljo first joined Novartis (then Lek) as a student in 1993, in the quality assurance department. He started his full time career with the company in 1997, in Information Technology. During his more than 20-years career he held a number of leadership positions, in IT, Supply Chain Management, Procurement and Novartis Technical Operations. He successfully implemented a number of new systems and led large teams in country, regional and global positions.

In the last couple of years he was Head of Supply Chain Management and Procurement for Lek d. d. and Sandoz d. d., as well as Slovenia Country representative for Novartis Business Services. Prior to his recent appointment as President of the Lek Management Board he was Global Head Novartis Technical Operations Procurement Strategy and Operation Excellence. During his career he received a number of Sandoz and Novartis Awards of excellence.

Robert holds a Master of Science in Management of Information Systems from the University in Maribor, as well as a Master of Business Administration (MBA) from Open University UK. He is further building his knowledge at different schools in Slovenia and abroad (IEDC Bled, IMD Lausanne, Harvard Business School, Novartis Leadership Training etc.).

* * *

Novartis is the leading provider of medicines in Slovenia, where Lek, Novartis Pharma Services and Sandoz, operate. Together we are building and maintaining the reputation of a dynamic, ethical, and trusted pharmaceutical company. Lek develops, manufactures, and markets effective, safe, and high quality medicines and active pharmaceutical ingredients. With our knowledge, quality, and experience we have gained an important role in Novartis' organizational structure, especially in the Novartis Technical Operations, Global Drug Development, Novartis Business Services, and the generic division Sandoz. We are the leading Sandoz development center, and one of the key development sites for technologically complex projects. We invest a great deal in the development, education, and training of our employees. Novartis invested in Slovenia more than EUR 2.3 billion since 2003. More than half of this investment has been devoted to development, and the rest to modernize and expand our production capacities.

Sandoz is a global leader in generic pharmaceuticals and biosimilars. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people's lives. We contribute to society's ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our broad portfolio of high-quality medicines, covering all majortherapeutic areas and increasingly focused on value-adding differentiatedmedicines, accounted for 2018 sales of USD 9.9 billion. Sandoz is headquartered in Holzkirchen, in Germany's Greater Munich area.

Sandoz is on Twitter. Sign up to follow @Sandoz_global at http://twitter.com/Sandoz_Global

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108 thousand people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com. 

* * *

This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.

- end -

For additional information contact:
Katarina Klemenc
Corporate Communications 
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32